Pipeline

Synergy IMT groundbreaking therapeutics with potential as standalone or combination therapy to treat a broad range of cancers

Our Pipeline

Synergy IMT is committed to progressing an initial candidate into clinical studies and forming collaborations around other candidates

SYN120

A bispecific T cell engaging antibody specific for sTA4. A tumor antigen that was selected for direct tumor cytotoxicity, for potential anti-metastatic and anti- protumor TME cell activity

SYN220

An antibody drug conjugate (ADC) that targets an sTA that is broadly expressed on different tumor types including colon, breast, gastric and pancreatic. A tumor antigen that was selected for direct tumor cytotoxicity, and rationale for anti-metastatic and anti- protumor TME cell activity.

SYN320

Several multispecific recombinant proteins with anti-tumor activity have been designed to target sTA.

Recombinant Protein Therapeutic
Colon Tumor Xenograft Study
Dosed IV @0.5mg/kg